VALANX Biotech announces successful fundraise of 2.3 M EUR
Platform for the conjugation of proteins is to find broad application in drug development and diagnostics
VALANX Biotech specializes in the precise production of defined protein-drug conjugates for the pharmaceutical industry. The company, founded by Michael Lukesch and based in the xista science park in Klosterneuburg, Austria, is researching and developing protein expression systems that allow the company’s own synthetic amino acids to be incorporated into any protein at freely selectable positions in multiple copies. With the help of click chemistry, the modified proteins can be quickly and reliably combined with other molecular units. Put simply, VALANX uses innovative techniques from synthetic biology to offer creative solutions to a previously intractable problem for customers in the pharmaceutical industry and beyond. This opens new avenues for drug development.
In spring 2020, a six-figure seed investment was made by a syndicate consisting of IST cube, tecnet equity and SOSV from the USA. The company is now announcing subsequent growth financing consisting of equity and public funding in the amount of EUR 2.3 million. The lead investor this time is SkyGene from Lower Austria, which is investing in VALANX for the first time. The existing investors xista science ventures (formerly IST cube), tecnet equity and SOSV have also participated in this financing round.
“We see a rapidly growing need for a simple but highly precise technology platform for protein conjugation and the development of new click chemistry for the delivery of complex biotherapeutics. VALANX efforts, enabled by the innovative use of a patented synthetic amino acid as well as modern CRISPR strategies, and first successes of the proprietary Interleukin-2 conjugate, were the key reasons for our investment”, explains Ingo Nagler of SkyGene.
Michael Lukesch, founder and CEO of VALANX Biotech, emphasizes: “Since our foundation in 2017, we have been working on a technology that will help pharmaceutical and biotechnology companies to produce protein drugs faster and more reliably. Our process allows protein conjugates to be precisely defined in terms of their molecular composition, which offers a significant advantage in terms of both production and drug safety.”
“Now we want to expand our team, further develop our revolutionary protein conjugation technology and intensify our contacts with industrial partners,” says Lukesch.
Doris Agneter, CEO of tecnet equity: “VALANX makes the conjugates usable as a tool for completely new applications in the pharmaceutical industry. As an investor, we are creating the environment in which this disruptive technology can develop its full potential. Our latest investment in VALANX enables world-class research and development work in Lower Austria.”
“It’s great to see how a scientific idea on how to solve a practical problem in the pharmaceutical industry has developed into a well-established company that is about to create a real impact with its technology,” says Alexander Schwartz from xista science ventures.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
